Matinas Biopharma Holdings Inc   (MTNB)
Other Ticker:  
Price: $0.2049 $-0.01 -2.429%
Day's High: $0.2211 Week Perf: -12.44 %
Day's Low: $ 0.20 30 Day Perf: -1.96 %
Volume (M): 2,158 52 Wk High: $ 0.89
Volume (M$): $ 442 52 Wk Avg: $0.39
Open: $0.21 52 Wk Low: $0.11

 Market Capitalization (Millions $) 45
 Shares Outstanding (Millions) 217
 Employees 230
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Matinas Biopharma Holdings Inc
Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative lipid-based pharmaceuticals. The company was founded in 2011 and is headquartered in Bedminster, New Jersey. Matinas Biopharma Holdings Inc. is committed to improving patients' lives by developing products that target unmet medical needs in infectious and inflammatory diseases.

Matinas Biopharma Holdings Inc. is focused on developing its proprietary lipid nanocrystal (LNC) delivery technology, which enables the enhanced absorption and targeted delivery of a wide range of therapeutic agents. The LNC technology is designed to improve the bioavailability of poorly soluble drugs, reduce toxicity, and enhance therapeutic efficacy. It has the potential to significantly impact the treatment of infectious and inflammatory diseases, including HIV/AIDS, hepatitis C, and cryptococcal meningitis.

Matinas Biopharma Holdings Inc. has a broad pipeline of products in development. The lead product candidate is MAT9001, an omega-3 fatty acid-based cardiovascular drug. MAT9001 is a prescription-only, omega-3 free fatty acid drug that is designed to treat patients with high triglycerides, a risk factor for cardiovascular disease. The company is also developing MAT2203, a LNC-formulated amphotericin B drug for the treatment of invasive fungal infections, including aspergillosis and candidiasis. The drug is currently in Phase 2 clinical trials.

The company has a team of experienced leaders and scientists, with expertise in drug development, pharmaceutical manufacturing, clinical research, and regulatory affairs. Matinas Biopharma Holdings Inc. has partnerships and collaborations with leading academic institutions, pharmaceutical companies, and government agencies to accelerate the development of innovative therapeutics.

In summary, Matinas Biopharma Holdings Inc. is a rapidly evolving biopharmaceutical company that is committed to improving the delivery of therapeutic agents for patients suffering from infectious and inflammatory diseases. With a pipeline of products in development and a team of experienced leaders and scientists, the company is well-positioned to create new and innovative treatments that will impact the lives of patients in need.

   Company Address: 1545 Route 206 South Bedminster 7921 NJ
   Company Phone Number: 484-8805   Stock Exchange / Ticker: NYSEAMER MTNB
   MTNB is expected to report next financial results on March 14, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.

Procyon Corporation

Procyon Corporation Steams Ahead, Consolidating Revenue at PCYN in Record-breaking Quarter

Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.

China Health Industries Holdings Inc

Impressive 11.069% Revenue Surge Demonstrates China Health Industries Holdings Inc's Strong Growth Potential in Q3 2023

China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.

Acer Therapeutics Inc

Acer Therapeutics Inc Reports Revenue of $0.37179 Million in Q3 2023 Financial Report amidst Concerns of Declining Stock Performance

The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.

Baudax Bio Inc

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period

Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com